AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31290406 — intervention group
Group type: EXPERIMENTAL
Intervention: VR Personality Project
Number of subjects: 159
Study 31290406 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based GM intervention
Number of subjects: 159
Study 31290406 — intervention group
Group type: COMPARATOR
Intervention: Active Web-based control
Number of subjects: 159
Study 31291010 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine intent
Number of subjects: 103
Study 31291010 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider recommendation for the HPV vaccine
Number of subjects: 103
Study 31291010 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive general attitude toward vaccines
Number of subjects: 103
Study 31291010 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived severity of HPV disease
Number of subjects: 103
Study 31291010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine intent
Number of subjects: 103
Study 31291010 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of survivors
Number of subjects: 103
Study 31291057 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (E-ART); provided to 105 FSWs; retention at end of study: 59.0% (62/105); mean duration of follow-up: 13.4 (±7.9) months; self-reported adherence over 90%.
Number of subjects: 442
Study 31291057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP); provided to 256 FSWs; retention at end of study: 47.3% (121/256); mean duration of follow-up: 11.8 (±7.9) months; adherence decreased from 78.4% to 56.7% (p-trend < 0.0001).
Number of subjects: 442
Study 31291801 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-integrated diagnostic parameters including fluid index flag, atrial fibrillation flag, and activity flag.
Number of subjects: 1036
Study 31291801 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-integrated diagnostic-positive patients in the high-risk MAGGIC cohort.
Number of subjects: 1036
Study 31291801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical and device diagnostic parameters.
Number of subjects: 1036
Study 31291850 — intervention group
Group type: EXPERIMENTAL
Intervention: DSC-PWI
Number of subjects: 221
Study 31291850 — intervention group
Group type: COMPARATOR
Intervention: T2*GRE
Number of subjects: 221
Study 31291985 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor combined with high-dose cytarabine (HiDAC) and mitoxantrone (Mito)
Number of subjects: 26
Study 31292118 — intervention group
Group type: EXPERIMENTAL
Intervention: POD24 (progression of disease within 24 months from diagnosis)
Number of subjects: 321
Study 31292118 — intervention group
Group type: COMPARATOR
Intervention: No POD24
Number of subjects: 321
Study 31292118 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for splenic and extranodal MZLs
Number of subjects: 321
Study 31292122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugary drinks consumption (100mL/d increase)
Number of subjects: 101257
Study 31292122 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% fruit juice consumption
Number of subjects: 101257
Study 31292122 — intervention group
Group type: COMPARATOR
Intervention: Artificially sweetened beverages consumption
Number of subjects: 101257
Study 31292141 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular complications (neuropathy, nephropathy, retinopathy) in patients with DM and HFpEF
Number of subjects: 2800
Study 31292141 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 2800
Study 31292141 — intervention group
Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 2800
Study 31292177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration of corticosteroids and anaesthetic
Number of subjects: 0
Study 31292177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration with inflammation
Number of subjects: 0
Study 31292177 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular infiltration without inflammation
Number of subjects: 0
Study 31292728 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Mastication Observation and Evaluation (T-MOE) instrument
Number of subjects: 80
Study 31292728 — intervention group
Group type: COMPARATOR
Intervention: Typical children without chewing disorders
Number of subjects: 80
Study 31292901 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) treatment for 14 days
Number of subjects: 24
Study 31293437 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Number of subjects: 0
Study 31293437 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31294009 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ballet intervention
Number of subjects: 0
Study 31294762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab therapy (200 mg every 21 days for 8 cycles, with provision to continue to 16 cycles)
Number of subjects: 51
Study 31294762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab therapy
Number of subjects: 51
Study 31295674 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab (a humanized monoclonal antibody to IL-5), administered for 52 weeks
Number of subjects: 610
Study 31295674 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 610
Study 31296082 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTA vascular closure device (14F used in 42 cases, 18F used in 221 cases)
Number of subjects: 341
Study 31296082 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTA vascular closure device
Number of subjects: 341
Study 31296099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of Cer-16
Number of subjects: 4249
Study 31296099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of SM-16
Number of subjects: 4249
Study 31296099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of Cer-22
Number of subjects: 4249
Study 31296099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of SM-20
Number of subjects: 4249
Study 31296099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of SM-22
Number of subjects: 4249
Study 31296099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of SM-24
Number of subjects: 4249
Study 31296225 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index (calculated using Ln(fasting triglycerides (mg/dl) × fasting blood glucose (mg/dl)/2))
Number of subjects: 2330
Study 31296225 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate consumption and lower lipid consumption
Number of subjects: 2330
Study 31296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (20 mg) plus obinutuzumab (1000 mg) as induction therapy for six 28-day cycles.
Number of subjects: 89
Study 31296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg) plus obinutuzumab (1000 mg) for 1-year maintenance (12 28-day cycles; days 2-22) and obinutuzumab (1000 mg) for 1-year maintenance (six 56-day cycles; day 1).
Number of subjects: 89
Study 31296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with lenalidomide plus obinutuzumab.
Number of subjects: 89
Study 31296643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable intake
Number of subjects: 472
Study 31296643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit intake
Number of subjects: 472
Study 31296923 — intervention group
Group type: COMPARATOR
Intervention: Post-operative CEA ≤ 2.35 ng/mL
Number of subjects: 899
Study 31296923 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative CEA > 2.35 ng/mL
Number of subjects: 899
Study 31296923 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of oxaliplatin to adjuvant treatment
Number of subjects: 899
Study 31296992 — intervention group
Group type: EXPERIMENTAL
Intervention: AOM 400 (aripiprazole once-monthly 400 mg)
Number of subjects: 340
Study 31296992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 31297046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic Suggestion
Number of subjects: 0
Study 31297046 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct-Current Stimulation
Number of subjects: 0
Study 31297046 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31297231 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 14 days
Number of subjects: 651
Study 31297231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study 31297236 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH lifestyle intervention
Number of subjects: 10
Study 31297636 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04136309 (CCR2 inhibitor) plus nab-paclitaxel (125 mg/m2) and gemcitabine
Number of subjects: 0
Study 31297647 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (HT) with aromatase inhibitors
Number of subjects: 39
Study 31297671 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-automated 3D-TEE measurements
Number of subjects: 67
Study 31297671 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated 3D-TEE measurements
Number of subjects: 67
Study 31297671 — intervention group
Group type: COMPARATOR
Intervention: Semi-automated THV sizing
Number of subjects: 67
Study 31297671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-class correlation coefficients of semi-automated method
Number of subjects: 67
Study 31297947 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with DPP-4 inhibitors
Number of subjects: 14668
Study 31297947 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with sulphonylureas
Number of subjects: 14668
Study 31297947 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with sodium-glucose co-transporter-2 inhibitors
Number of subjects: 14668
Study 31297947 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy combinations of metformin with glucagon-like peptide-1 receptor agonists
Number of subjects: 14668
Study 31297947 — intervention group
Group type: COMPARATOR
Intervention: First-line metformin monotherapy
Number of subjects: 14668
Study 31297947 — intervention group
Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 14668
Study 31298221 — intervention group
Group type: EXPERIMENTAL
Intervention: iBall intervention group (n=13)
Number of subjects: 23
Study 31298221 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 23
Study 31298221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 31298286 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized 6-day low-sodium diet to stimulate RAAS activation
Number of subjects: 0
Study 31298286 — intervention group
Group type: EXPERIMENTAL
Intervention: RAAS activation
Number of subjects: 0
Study 31298497 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy (E2 valerate and cyproterone acetate) prescribed at baseline until week 5, and then from week 8 until the end of study.
Number of subjects: 20
Study 31298497 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine initiated at week 3 and continued without interruption.
Number of subjects: 20
Study 31298551 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1-hour algorithm
Number of subjects: 2525
Study 31298551 — intervention group
Group type: COMPARATOR
Intervention: ESC 0/3-hour protocol
Number of subjects: 2525
Study 31298706 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-exendin-4 PET/CT plus MRI
Number of subjects: 6
Study 31298706 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 6
Study 31298706 — intervention group
Group type: COMPARATOR
Intervention: 68Ga-DOTA-exendin-4 PET/CT
Number of subjects: 6
Study 31298972 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Number of subjects: 0
Study 31299005 — intervention group
Group type: EXPERIMENTAL
Intervention: M6620 (ATR inhibitor) and cisplatin
Number of subjects: 1
Study 31299007 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial measurement of optic nerve sheath diameter (ONSD) during therapy for DKA.
Number of subjects: 0
Study 31299074 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-based ART (600 mg daily)
Number of subjects: 57
Study 31299074 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine-based ART (200 mg twice daily)
Number of subjects: 57
Study 31299074 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving ART)
Number of subjects: 57
Study 31299246 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus and hydroxychloroquine
Number of subjects: 0
Study 31299468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FSC) treatment
Number of subjects: 2005
Study 31299650 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan administration
Number of subjects: 413
Study 31299650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clazosentan)
Number of subjects: 413
Study 31299906 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 13638
Study 31299966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer care coordination nursing occupations (complex intervention)
Number of subjects: 0
Study 31299966 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical reference framework for care coordination in France
Number of subjects: 0
Study 31299966 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth analysis of practices, contexts, perceptions, and attitudes related to care coordination occupations
Number of subjects: 0
Study 31299966 — intervention group
Group type: EXPERIMENTAL
Intervention: Typology of nurse practices in cancer care coordination
Number of subjects: 0
Study 31299972 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) diagnosed with eGFR < 60 mL/min/1.73m²
Number of subjects: 2274
Study 31299988 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (abdominal procedures)
Number of subjects: 15
Study 31300344 — intervention group
Group type: EXPERIMENTAL
Intervention: MGN1703 (TLR9 agonist) for 24 weeks
Number of subjects: 7
Study 31300360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg daily
Number of subjects: 73
Study 31300502 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously-Employed group
Number of subjects: 193
Study 31300502 — intervention group
Group type: COMPARATOR
Intervention: Employed-Unemployed group
Number of subjects: 193
Study 31300502 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with return to work
Number of subjects: 193
Study 31300820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SIMPLIFY) for 12 weeks
Number of subjects: 190
Study 31300820 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/dasabuvir/ombitasvir ± ribavirin (D3FEAT) for 12 weeks
Number of subjects: 190
Study 31300969 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 361
Study 31300969 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 361
Study 31300969 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 361
Study 31300969 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs/ARBs
Number of subjects: 361
Study 31300969 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 361
Study 31300973 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI
Number of subjects: 69
Study 31300979 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 677
Study 31301122 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoid ingestion and cold exposure
Number of subjects: 20
Study 31301251 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS-HS index (including BMI percentile, waist circumference, ALT, and SHBG)
Number of subjects: 108
Study 31301251 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort of PCOS-HS index
Number of subjects: 108
Study 31301430 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographically normal knees with contralateral joint space narrowing (JSN)
Number of subjects: 120
Study 31301430 — intervention group
Group type: COMPARATOR
Intervention: Bilaterally normal knees (KLG0)
Number of subjects: 120
Study 31301853 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sarnat score of ≥5 performed at <6 hours of age
Number of subjects: 0
Study 31301920 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine live (ZVL)
Number of subjects: 1500000
Study 31301962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg + Pembrolizumab 200 mg
Number of subjects: 92
Study 31301962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg + Pembrolizumab 200 mg
Number of subjects: 92
Study 31301962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab + Pembrolizumab
Number of subjects: 92
Study 31302044 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma eicosapentaenoic acid (EPA) abundance (%EPA) measured at baseline
Number of subjects: 6562
Study 31302344 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CTx) with TS-1 (35 mg/m²) for two 21-day courses followed by chemoradiotherapy (CCRT)
Number of subjects: 42
Study 31302639 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe aortic stenosis management
Number of subjects: 2171
Study 31302640 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine via ultrasound-guided nerve stimulator-assisted subgluteal sciatic nerve block
Number of subjects: 86
Study 31303133 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer carotid stents
Number of subjects: 0
Study 31303142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus rilpivirine
Number of subjects: 0
Study 31303143 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline concordant care for long-term opioid therapy
Number of subjects: 0
Study 31303143 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31303280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing salmon's milt extract, 1 capsule per day for the first 4 weeks, then 1 capsule in the morning and 1 capsule in the evening for the remaining 8 weeks
Number of subjects: 87
Study 31303280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing salmon's milt extract
Number of subjects: 87
Study 31303280 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 20; 15 women, 5 men; age range 25-65 years)
Number of subjects: 87
Study 31303427 — intervention group
Group type: EXPERIMENTAL
Intervention: McArdle sign (greater than 10% neck flexion-induced reduction in strength)
Number of subjects: 106
Study 31303427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and quantitative measures of McArdle sign
Number of subjects: 106
Study 31303427 — intervention group
Group type: COMPARATOR
Intervention: Receiver operating characteristic curve
Number of subjects: 106
Study 31303427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of McArdle sign measurements
Number of subjects: 106
Study 31303457 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood count control (≥1 controlled blood count)
Number of subjects: 1714
Study 31303457 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood count control (≥2 controlled blood counts)
Number of subjects: 1714
Study 31303457 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete hematologic remission (CHR)
Number of subjects: 1714
Study 31303457 — intervention group
Group type: COMPARATOR
Intervention: No blood count control
Number of subjects: 1714
Study 31303642 — intervention group
Group type: EXPERIMENTAL
Intervention: DigniCap® scalp-cooling system
Number of subjects: 139
Study 31303643 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-400945 at 64 mg/day
Number of subjects: 43
Study 31303643 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-400945 at 96 mg/day
Number of subjects: 43
Study 31303643 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-400945 at 72 mg/day
Number of subjects: 43
Study 31303643 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-400945 at 3 to 96 mg/day
Number of subjects: 43
Study 31303643 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-400945
Number of subjects: 43
Study 31304019 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome and smoking
Number of subjects: 0
Study 31304019 — intervention group
Group type: COMPARATOR
Intervention: Infertile men
Number of subjects: 0
Study 31304320 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based diagnostic system
Number of subjects: 900
Study 31304320 — intervention group
Group type: COMPARATOR
Intervention: Wisconsin Fundus Photograph Reading Center (FPRC) widefield stereoscopic photography and macular Optical Coherence Tomography (OCT)
Number of subjects: 900
Study 31304365 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on modelling datasets (experimental group)
Number of subjects: 178
Study 31304365 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic parameters (control group)
Number of subjects: 178
Study 31304455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun exposure
Number of subjects: 0
Study 31304455 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin reflectance
Number of subjects: 0
Study 31304455 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity
Number of subjects: 0
Study 31304801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Number of subjects: 0
Study 31304973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 31
Study 31304973 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep
Number of subjects: 31
Study 31304973 — intervention group
Group type: COMPARATOR
Intervention: Baseline (8 hours of wakefulness)
Number of subjects: 31
Study 31305924 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (Norditropin) prescribed according to local practice
Number of subjects: 19847
Study 31306033 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31306183 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CAM
Number of subjects: 176